8-K
filed April 21, 2025, 7:59 PM ET
ticker IMVT
CIK 0001764013
leadership
confidence high
sentiment positive
materiality 0.80
Immunovant appoints new CEO/CFO, expands IMVT-1402 into Sjögren's and CLE
Immunovant, Inc.
- CEO Peter Salzmann retired; Eric Venker (Roivant President) appointed CEO, effective April 21.
- CFO Renee Barnett stepped down; Tiago Girao appointed CFO with $481K salary and $6.66M equity award.
- Board changes: George Migausky resigned; Robert Susman and Jacob Bauer appointed as directors.
- IMVT-1402 IND cleared for potential registrational study in Sjögren's disease, start summer 2025.
- Proof-of-concept study in Cutaneous Lupus Erythematosus initiated; cash runway through Graves' readout in 2027.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Peter Salzmann retired as Member of Board of Directors at Immunovant, Inc..
- Action
- retired
- Role
- Member of Board of Directors
Exact text from the filing
and as a member of the Company’s Board of Directors (the “Board”), effective April 18, 2025.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Robert Susman was appointed as Member of Board of Directors at Immunovant, Inc..
- Action
- appointed
- Role
- Member of Board of Directors
Exact text from the filing
the Board appointed Robert Susman and Jacob Bauer to fill the vacancies on the Board created by the departure of each of Dr. Salzmann and Mr. Migausky
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jacob Bauer was appointed as Member of Board of Directors at Immunovant, Inc..
- Action
- appointed
- Role
- Member of Board of Directors
Exact text from the filing
the Board appointed Robert Susman and Jacob Bauer to fill the vacancies on the Board created by the departure of each of Dr. Salzmann and Mr. Migausky
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Peter Salzmann retired as Chief Executive Officer at Immunovant, Inc..
- Action
- retired
- Role
- Chief Executive Officer
Exact text from the filing
Peter Salzmann, M.D. retired from his roles as the Chief Executive Officer and principal executive officer of Immunovant, Inc. (the "Company" or "Immunovant"), effective April 20, 2025
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
George Migausky resigned as Member of Board of Directors at Immunovant, Inc..
- Action
- resigned
- Role
- Member of Board of Directors
Exact text from the filing
On April 18, 2025, George Migausky, a member of Immunovant’s Board and Chair of the Audit Committee of the Board (the “Audit Committee”), resigned from the Board and the Audit Committee, effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Renee Barnett departed as Chief Financial Officer at Immunovant, Inc..
- Action
- ceased serving
- Role
- Chief Financial Officer
Exact text from the filing
Also effective April 20, 2025, Renee Barnett ceased serving as the Chief Financial Officer (including the principal financial officer and principal accounting officer) of the Company.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.